+A -A

Comparative View:

2Q20 Create chart
Net sales revenues 1,046,439
Change in Fair Value of Biological Assets 52,439
Cost of Goods Sold -706,845
Depreciation / Amortization / exhaustion -104,493
Exhaustion of biological assets -19,079
Gross Profit 268,461
Selling Expenses -173,284
General and Administrative Expenses -54,866
Management Compensation -4,339
Other Operating Compensation -3,564
Equity income from subsidiaries -24,076
Operating Profit before Financial Income and Equity 8,332
Financial Income 34,105
Financial Expenses -67,698
Income Before Income Tax and Social Contribution -25,261
Income and social contribution taxes - current -9,721
Income Tax and Social Contribution - Deferred 11,400
Effect profit from discontinued operation null
Net Income -23,582
Recurring Net Income -21,376
Recurring EBITDA 119,023
EBITDA Margin 11.4 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza